Fierce Pharma
AUGUST 16, 2024
It’s time once again to nominate the fiercest women you know in the life science industry for our annual list. | It’s time once again to nominate the fiercest women you know in the life science industry for our annual list.
MedCity News
AUGUST 16, 2024
Fair Square Medicare launched a new generative AI platform called Vox. It’s meant to be used by Medicare carriers and brokerages and has three main features: AI voice agents, generative AI-driven insights and AI-powered coaching. The post Fair Square Medicare Unveils Generative AI Platform for Medicare Organizations appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 16, 2024
Even as supplies of Novo Nordisk’s immensely popular GLP-1 drugs Ozempic and Wegovy start to stabilize, the Danish drugmaker continues to announce manufacturing and capacity upgrades at a rapid cli | Novo Nordisk Pharmatech, a unit that specializes in producing drug ingredients, is spending 1.5 billion Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make raw materials, the company said Friday.
MedCity News
AUGUST 16, 2024
To change the trajectory of the youth mental health pandemic, we must commit to “bending the curve” by building strong, prevention-oriented partnerships. Collaboration between caretakers, schools, and mental health professionals is vital. The post Bend the Curve: Schools’ Crucial Role in Early Intervention for Youth Mental Health appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
AUGUST 16, 2024
After knocking out multiple personal injury lawsuits this summer, GSK has prevailed on another front in its long-running Zantac litigation. | After knocking out multiple personal injury lawsuits this summer, GSK has prevailed on another front in its long-running Zantac litigation, thanks to a decision in Florida that put the kibosh on suspect expert testimony.
MedCity News
AUGUST 16, 2024
Abbott and Medtronic — typically regarded as competitors — have recently joined forces. The two companies teamed up to collaborate on a continuous glucose monitoring system that combines Abbott’s FreeStyle Libre technology with Medtronic’s automated insulin delivery system. The post When Foes Become Friends: Abbott Teams Up With Medtronic appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 16, 2024
Despite achieving strong responses against influenza A, a Phase 3 test of a Pfizer and BioNTech flu and Covid-19 combination vaccine did not meet goals against less common influenza B. These results come two months after Moderna’s combination vaccine succeeded in its Phase 3 trial. The post Pfizer, BioNTech Flu and Covid-19 Combo Vaccine Falls Short Against Influenza B Strain appeared first on MedCity News.
Fierce Pharma
AUGUST 16, 2024
Merck licensed a bispecific from a Chinese biotech with plans to target oncology and autoimmune diseases. Legend Biotech is taking a close at its business as M&A has emerged as an option. | Merck licensed a bispecific from a Chinese biotech with plans to target oncology and autoimmune diseases. Legend Biotech is taking a close at its business as M&A has emerged as an option.
MedCity News
AUGUST 16, 2024
Check out news from Alpha Sophia, MD Ally, Guardoc Health, and more. The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.
Fierce Pharma
AUGUST 16, 2024
Months after securing the full rights to anti-CD19 antibody Monjuvi (tafasitamab) from partner MorphoSys, Incyte has the data to potentially back a label expansion into lymphoma. | The company looks to file its drug for a follicular lymphoma indication as part of a later-line triple combo therapy by the end of the year.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
AUGUST 16, 2024
AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.PD-L1 inhibitor Imfinzi (durvalumab) has been cleared for use in adult patients who need surgery for early-stage (IIA-IIIB) NSCLC and have no ALK or EGFR mutations that would make them suitable for targeted therapies.
Fierce Pharma
AUGUST 16, 2024
Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. | Immunic Therapeutics CEO Daniel Vitt details the firm’s new oral MS therapy, vidofludimus calcium. Learn how this dual-action treatment could revolutionize MS care by addressing both relapses and disease progression.
pharmaphorum
AUGUST 16, 2024
As WHO declares mpox an emergency, the only recognised drug treatment for the virus, Siga's tecovirimat, fails a clinical trial.
Pharmaceutical Commerce
AUGUST 16, 2024
The latest news for pharma industry insiders.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
AUGUST 16, 2024
A culture of compliance means truly valuing an adherence to industry standards, rather than looking at SOPs as a series of boxes that need to be checked in order to claim that requirements have been met. The post Corporate Compliance in the Era of TEFCA appeared first on MedCity News.
Pharmaceutical Commerce
AUGUST 16, 2024
In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.
Pharmaceutical Technology
AUGUST 16, 2024
The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.
pharmaphorum
AUGUST 16, 2024
Lykos Therapeutics is slashing staff after the FDA turned down its MDMA-assisted therapy for PTSD, while founder Rick Doblin is stepping down.
PharmaTimes
AUGUST 16, 2024
This form of cancer was responsible for 1.
Pharmaceutical Technology
AUGUST 16, 2024
Genomic medicines offer new techniques for treating conditions once thought to be intractable - a world of opportunity awaits.
PharmaTimes
AUGUST 16, 2024
The study yielded over one million dose-responsive curves for existing cancer drugs
Pharmaceutical Commerce
AUGUST 16, 2024
By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
AUGUST 16, 2024
While the vaccine demonstrated high responses for neutralizing influenza A titers, it failed to show sufficient efficacy against influenza B.
Pharmatutor
AUGUST 16, 2024
The New Penal Processes in Pharmacy Act admin Fri, 08/16/2024 - 15:29 ABOUT AUTHOR Dr. R. S. Thakur Former Secretary, Pharmacy Council of India. Email : drramsthakur@gmail.
Pharmaceutical Technology
AUGUST 16, 2024
Bavarian Nordic aims to gain a label expansion for adolescents in Europe in Q4 this year, whilst it prepares a trial in children in Africa.
PharmaVoice
AUGUST 16, 2024
The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.
Pharmacy Times
AUGUST 16, 2024
Durvalumab is a human monoclonal antibody that targets and binds to PD-L1 to interrupt tumor immune-evasion tactics.
Nixon Gwilt Law
AUGUST 16, 2024
In the rapidly evolving landscape of US healthcare, digital health solutions are proliferating at an unprecedented rate. While these innovations offer remarkable benefits for patient outcomes and reduced costs, they have also introduced the challenge of “point solution fatigue.” This term refers to the overwhelming number of single-function “pure-play” digital health tools, each designed to solve a specific problem.
Pharmacy Times
AUGUST 16, 2024
The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.
Clear Pivot
AUGUST 16, 2024
When I've been talking with prospects over the past few months, I've been seeing increasing confusion in what types of sales and marketing email tools there are and how they should be used. But it is VERY important to know the differences and why. If you use the wrong tools for the wrong job, you could cause some real damage, including even getting suspended by your email marketing provider or burning down your email domain reputation.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
316 
Let's personalize your content